Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  03:46 2022-11-30 pm EST
10.98 USD   +1.67%
11/29Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
11/29Alx Oncology : Corporate Presentation
PU
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu in Breast Cancer

08/15/2022 | 09:54am EST


ę MT Newswires 2022
All news about ALX ONCOLOGY HOLDINGS INC.
11/29Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
11/29Alx Oncology : Corporate Presentation
PU
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
11/29ALX Oncology Holdings Inc. Appoints Scott Garland to Its Board of Directors
CI
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual..
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains B..
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
GL
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -131 M - -
Net cash 2022 255 M - -
P/E ratio 2022 -3,40x
Yield 2022 -
Capitalization 440 M 440 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 55
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 10,80 $
Average target price 35,00 $
Spread / Average Target 224%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. GarcÝa Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-49.74%440
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.22%31 776
GENMAB A/S20.91%28 866